Skip to content

US · MANE · BIOTECHNOLOGY

Veradermics, Incorporated (MANE) intrinsic value and stock valuation

$119.52as of 2026-11-21 · Mkt cap 4.65B

Data updated · price as of 2026-11-21

IC valuationIntrinsic value, upside vs price and the fair-value band are available to Pro members.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Veradermics, Incorporated DCF and intrinsic value

InvestorsCraft values MANE with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from MANE’s statements →

Veradermics, Incorporated Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Biotechnology New Haven, CT 06513 veradermics.com

How the business is doing

Fiscal 2023–2025, USD

Revenue
$0.00
20232025
Net income
-$-70M
20232025
Free cash flow
-$-71.63M
20232025
Total equity
-$-121.01M
20232025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2023–2025, USD
202520242023
Revenue$0.00$0.00$0.00
Operating income-$-72.35M-$-26.78M-$-17.32M
Net income-$-70M-$-26.49M-$-16.49M
EPSd-$-2M-$-131.58K-$-81.91K
Operating cash flow-$-71.6M-$-23.69M-$-13.51M
Capital expenditure-$-20K$0.00$0.00
Free cash flow-$-71.63M-$-23.69M-$-13.51M
Total assets$152.6M$59.4M$18.5M
Total debt$0.00$0.00$790K
Net debt-$-21.76M-$-53.08M-$-15.51M
Total equity-$-121.01M$54.7M$14.6M
Cash and short-term investments$141.9M$53.1M$16.3M
Income statement
202520242023
Revenue$0.00$0.00$0.00
Cost of revenue$0.00$0.00$0.00
Gross profit$0.00$0.00$0.00
Research and development expenses$62.1M$23.3M$15M
Selling, general and administrative expenses$10.3M$3.5M$2.35M
Other expenses$0.00$0.00$0.00
Operating expenses$72.4M$26.8M$17.3M
Cost and expenses$72.4M$26.8M$17.3M
Interest income$1.56M$480K$870K
Interest expense$0.00$580K$40K
Depreciation and amortization$0.00$0.00$0.00
Ebitda-$-70M-$-25.9M-$-16.45M
Operating income-$-72.35M-$-26.78M-$-17.32M
Total other income/expenses, net$2.35M$290K$830K
Income before tax-$-70M-$-26.49M-$-16.49M
Income tax expense$0.00$0.00$0.00
Net income-$-70M-$-26.49M-$-16.49M
Weighted average shares outstanding$35.1M$201.3M$201.3M
Weighted average diluted shares outstanding$35.1M$201.3M$201.3M
Balance sheet
202520242023
Cash and short-term investments$141.9M$53.1M$16.3M
Net receivables$1.25M$1.38M$0.00
Inventory$0.00$0.00$0.00
Total current assets$152.5M$55.5M$17.6M
Property, plant and equipment, net$120K$0.00$0.00
Goodwill and intangible assets$0.00$0.00$0.00
Long-term investments$0.00$3.85M$890K
Total non-current assets$120K$3.85M$890K
Total assets$152.6M$59.4M$18.5M
Accounts payable$2.13M$2.25M$1.85M
Short-term debt$0.00$0.00$0.00
Deferred revenue$0.00$0.00$0.00
Total current liabilities$9.15M$4.72M$3.05M
Long-term debt$0.00$0.00$790K
Deferred revenue, non-current$0.00$0.00$0.00
Total non-current liabilities$264.5M$99.3M$790K
Capital lease obligations$0.00$0.00$0.00
Total liabilities$273.6M$4.72M$3.84M
Common stock$0.00$0.00$0.00
Retained earnings-$-123.42M-$-49.23M-$-22.74M
Accumulated other comprehensive income (loss)$60K$0.00$0.00
Total equity-$-121.01M$54.7M$14.6M
Total investments$120.1M$3.85M$890K
Total debt$0.00$0.00$790K
Net debt-$-21.76M-$-53.08M-$-15.51M
Cash flow statement
202520242023
Net income-$-70M-$-26.49M-$-16.49M
Depreciation and amortization$0.00$0.00$0.00
Stock-based compensation$1.44M$250K$210K
Change in working capital-$-3.89M$730K$920K
Accounts receivable$0.00$0.00$0.00
Inventory$0.00$0.00$0.00
Accounts payable-$-120K$650K$1.35M
Net cash provided by operating activities-$-71.6M-$-23.69M-$-13.51M
Investments in property, plant and equipment-$-20K$0.00$0.00
Acquisitions, net$0.00$0.00$0.00
Net cash used for investing activities-$-118.86M$0.00$0.00
Common stock issued$160K$52.8M$0.00
Common stock repurchased$0.00$0.00$0.00
Dividends paid$0.00$0.00$0.00
Net cash used for financing activities$159.1M$60.5M$13.9M
Net change in cash-$-31.32M$36.8M$390K
Cash at end of period$21.8M$53.1M$16.3M
Operating cash flow-$-71.6M-$-23.69M-$-13.51M
Capital expenditure-$-20K$0.00$0.00
Free cash flow-$-71.63M-$-23.69M-$-13.51M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Veradermics, Incorporated

        Veradermics, Incorporated functions as a biopharmaceutical enterprise focused on devising pioneering therapeutic interventions for various skin and cosmetic disorders. The company's development pipeline includes treatments for Pattern Hair Loss (PHL), impacting both adult and pediatric demographics. A flagship offering is VDPHL01, an orally administered, non-hormonal medication specifically for chronic hair loss management in both male and female patients with PHL. Furthermore, Veradermics is progressing with VDMN, an innovative dissolvable microarray patch technology employing immunotherapy for common warts. Its research also extends to VDAA for addressing alopecia areata, and VDMC, aimed at molluscum contagiosum. Collectively, the firm's product candidates target conditions such as androgenetic alopecia, common warts, molluscum contagiosum, alopecia areata, and atopic dermatitis. Veradermics caters to healthcare practitioners and clinicians specializing in dermatologic and aesthetic care for patients of all ages, in addition to the wider medical and scientific community engaged in dermatology. Founded in 2019, the company is based in New Haven, Connecticut.

        CEO
        Reid Waldman
        Employees
        21
        Beta
        1.35

        Explore

        Frequently asked questions

        What is the intrinsic value of Veradermics, Incorporated (MANE)?

        InvestorsCraft does not currently publish an intrinsic value for MANE. How the IC value is calculated.

        Is MANE undervalued?

        InvestorsCraft does not publish an undervaluation signal for MANE at this time.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.